Lorlatinib was approved by the first -line treatment ALK non -small cell lung cancer!

Home > Health

Lorlatinib was approved by the first -line treatment ALK non -small cell lung cancer!

2022-06-24 06:08:54 2 ℃

Many small patients with lung cancer can benefit from targeted therapy. About 2%to 5%of non -small cell lung cancer patients have special gene changes called ALK mutations. This seems to be younger in non -smoking patients with advanced diseases. In the middle. Non -small cell lung cancer has always been one of the fastest areas of targeted therapy. In the field of non -small cell lung cancer, a number of "diamonds" targets including ROS1 and ALK were born, and the corresponding targeted drugs were very effective.

On March 4, 2021, the FDA approved the supplementary indications of Lorlatinib, Lorbrena, and officially raised this third -generation ALK inhibitor to the front line. On the basis of the most classic first -generation drug Kizotinib, Lauradinib pushed the therapeutic effect of ALK mutant non -small cell lung cancer to a brand new step!

Patients with lung cancer carrying ALK or ROS1 mutations are called "lucky people" in lung cancer because targeted drugs for ALK or ROS1 mutations not only have good effect, but also have many choices. Lorlatinib (Lorlatinib) is a new, reversible, powerful small molecule ALK and ROS1 inhibitor developed by Pfizer, which has a strong inhibitory effect on ALK's known resistance mutations.

The results of this approval based on the key III CROWN test (NCT03052608). In this "head -opposite" comparison test with Kizotinib, patients who received first -line treatment of Lauradinib were reduced by 72%of the risk of disease progress or death!

Compared with Kizotinib, Lauradini's most significant improvement is that it has a very strong brain activity. We all know that although Kazidinib the treatment of non -small cell lung cancer patients in the treatment of ALK mutations has a significant effect, it is difficult to effectively control the intracranial lesions of the brain metastases due to the large molecular weight and poor activity of the brain. Lauradinib's brain activity is good. In the treatment of brain metastases, it performs very brightly.

According to the results of public research at the World Ling Cancer Conference (WCLC) just ended recently, the overall relief rate of patients with brain metastases in the treatment baseline of Lauradinib for treatment was 82%, of which the complete relief rate was as high as 71%.

Patients receiving clipininib the treatment, the median no progressive survival period was 9.3 months, and patients who received Lauraidih treatment had not yet reached the no progressive survival period. Among the patients who were treated with Laurathinib, 79%of the patient's intracranial relief lasting for more than 12 months was 0. This data was 0 among the patients who were treated with clzidinib.

The efficacy data of the first -line treatment of Laurathinib has the successful approval of ALK to integrate lung cancer's latest first -line treatment option, which also means that more patients will benefit from it.